サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1376144

勃起不全治療薬の市場規模、シェア、動向分析レポート：製品別、地域別、セグメント予測、2023年～2030年

Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Zydena, Levitra, Stendra, Others), By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 79 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
勃起不全治療薬の市場規模、シェア、動向分析レポート：製品別、地域別、セグメント予測、2023年～2030年
出版日: 2023年10月18日
発行: Grand View Research
ページ情報: 英文 79 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

勃起不全治療薬市場の成長と動向：

Grand View Research, Inc.の最新調査によると、世界の勃起不全治療薬市場規模は2030年までに47億9,000万米ドルに達する見込みです。

同市場は2023年から2030年にかけてCAGR 8.8%で拡大する見込みです。勃起不全の有病率の増加が市場成長に寄与すると予想されます。欧州泌尿器科学会によると、2020年の40～70歳の欧州男性人口におけるEDの全体的な有病率は約52％であることが判明しています。また、ボストン大学医学部によると、40歳代男性人口の約22.0%、70歳代男性人口の約49.0%が勃起不全に罹患しています。このように、老年人口の増加は予測期間中にEDの有病率を増加させると予想され、市場に有利な成長機会を生み出すと期待されています。

イーライリリー・アンド・カンパニーは、リリー患者支援プログラム（LPSP）を通じて低価格で医薬品を提供し、ED患者を支援しています。このプログラムは、カナダ国内の適格なED保険未加入患者に経済的支援を提供するもので、このプログラムには登録が必要な場合があります。このように、シアリスのブランドバージョンにこのような支援プログラムが存在することで、低所得層の患者が購入しやすくなり、収益の増加にもつながる可能性があります。さらに、企業は海外市場における製品の製造・商業化のために、提携やパートナーシップなどの取り組みを行っています。例えば、2022年1月、ペトロス・ファーマシューティカルズ・インクは、アバナフィル錠剤の商業生産のために世界の製造受託機関（CDMO）と提携しました。この提携は、既存のビバス社との契約に代わり、製品供給を継続することを目的としています。

さらに、国立医学図書館（2021年）によると、中国本土のED患者を対象にステンドラの安全性と有効性を評価する第3相臨床試験が四川海斯古製薬有限公司によって実施されました。臨床試験の結果、ステンドラ100mgと200mgの2回投与により、中国のED患者に改善がみられました。このような臨床的有効性の証明により、Strenda（Avanafil）の市場での地位は強化されるかもしれないです。しかし、勃起不全に対する認識不足、治療に対する羞恥心、誤診、病気に関する社会的烙印、慎重さの欠如などが、市場の成長を抑制する可能性があります。欧州泌尿器科学会（EAU）が実施した調査によると、スペイン人のうちED治療について聞いたことがあるのはわずか18％であるのに対し、68.0％の人が治療効果を信じています。

勃起不全治療薬市場レポートハイライト

  • 製品別では、バイアグラが世界中で入手可能であることと、ED患者の間で同製品に対する認知度が高まっていることから、バイアグラ部門が2022年に最大の市場シェアを占めました。
  • 北米は勃起不全治療薬市場を独占し、2022年の売上高シェアは51.3%でした。これは、同地域の疾病負担の大きさ、医療インフラの充実、治療用新製品の迅速な承認が理由です。
  • アジア太平洋地域は、予測期間中に10.2%のCAGRで最も急速に成長すると予想されます。同地域の成長は、同地域への新製品の参入に起因します。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 勃起不全治療薬市場の変数、動向、範囲

  • 市場系統の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 勃起不全治療薬市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 勃起不全治療薬市場：製品の推定・動向分析

  • 勃起不全治療薬市場：重要なポイント
  • 勃起不全治療薬市場：製品動向と市場シェア分析、2022年および2030年
  • バイアグラ
  • シアリス
  • ザイデナ
  • レビトラ
  • ステンドラ
  • その他

第5章 勃起不全治療薬市場：地域の推定・動向分析

  • 地域別の見通し
  • 地域別の勃起不全治療薬市場：重要なポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • クウェート

第6章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Pfizer, Inc.
    • Eli Lilly and Company
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Sun Pharmaceutical Industries Ltd.
    • Bayer AG
    • Petros Pharmaceuticals, Inc.
    • VIVUS, Inc.
    • Auxilium Pharmaceuticals
    • Adamed
    • Cipla Inc.
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 3 North America erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 4 U.S. erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 5 Canada erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 6 Europe erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 7 Europe erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 8 Germany erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 9 UK erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 10 France erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 11 Italy erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 12 Spain erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 13 Sweden erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 14 Norway erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 15 Denmark erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 18 Japan erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 19 China erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 20 India erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 21 Australia erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 22 Thailand erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 23 South Korea erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 24 Latin America erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 25 Latin America erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 26 Brazil erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 27 Mexico erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 28 Argentina erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 29 Middle East and Africa erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 30 Middle East and Africa erectile dysfunction drugs market, by region, 2018 - 2030 (USD Million)
  • Table 31 South Africa erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 33 UAE erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)
  • Table 34 Kuwait erectile dysfunction drugs market, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Erectile dysfunction drugs: Market outlook
  • Fig. 9 Erectile dysfunction drugs: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Erectile dysfunction drugs market driver impact
  • Fig. 15 Erectile dysfunction drugs market restraint impact
  • Fig. 16 Erectile dysfunction drugs market strategic initiatives analysis
  • Fig. 17 Erectile dysfunction drugs market: Product movement analysis
  • Fig. 18 Erectile dysfunction drugs market: Product outlook and key takeaways
  • Fig. 19 Viagra market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 20 Cialis market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 21 Zydena market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 22 Levitra market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 23 Stendra market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 24 Others market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 25 Global erectile dysfunction drugs market: Regional movement analysis
  • Fig. 26 Global erectile dysfunction drugs market: Regional outlook and key takeaways
  • Fig. 27 North America market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 28 U.S. market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 29 Canada market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 30 Europe market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 31 UK market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 32 Germany market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 33 France market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 34 Italy market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 35 Spain market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 36 Sweden market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 37 Norway market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 38 Denmark market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 39 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 40 Japan market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 41 China market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 42 India market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 43 Australia market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 44 Thailand market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 45 South Korea market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 46 Latin America market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 47 Brazil market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 48 Mexico market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 49 Argentina market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 50 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 51 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 52 South Africa market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 53 UAE market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 54 Kuwait market estimates and forecasts, 2018 - 2030 (USD million)
目次
Product Code: 978-1-68038-604-2

Erectile Dysfunction Drugs Market Growth & Trends:

The global erectile dysfunction drugs market size is expected to reach USD 4.79 billion by 2030, according to a new study by Grand View Research, Inc.. The market is expected to expand at a CAGR of 8.8% from 2023 to 2030. The increasing prevalence of erectile dysfunction is expected to contribute to market growth. According to the European Association of Urology, the overall prevalence of ED was found to be around 52% in the European male population aged 40-70 years in 2020. In addition, according to the Boston University School of Medicine, approximately 22.0% of 40 years aged male population and 49.0% by age of 70 years are affected by erectile dysfunction. Thus, the increasing geriatric population is anticipated to increase the prevalence of ED over the forecast period and is expected to create lucrative growth opportunities in the market.

Eli Lilly and Company is supporting ED patients by offering medicine at low cost through Lilly Patient Support Program (LPSP). This program provides financial assistance to eligible ED uninsured patients in Canada who may require registration for this program. Thus, the presence of such supportive programs for a branded version of Cialis may increase the affordability of the lower-income patient population and also aid in generating increased revenue. Moreover, companies have undertaken initiatives such as collaboration and partnership for the manufacturing and commercialization of products in the overseas market. For instance, in January 2022, Petros Pharmaceuticals Inc. partnered with a global Contract Manufacturing Organization (CDMO) for the commercial production of Avanafil tablets. This partnership was formed with an aim to replace the existing agreement with Vivus Inc. and continue product supply.

Furthermore, according to the National Library of Medicine (2021), a phase 3 clinical trial was conducted by Sichuan Haisco Pharmaceutical Co., Ltd. to evaluate the safety and efficacy of Stendra in patients with ED in mainland China. The results of the clinical trial showed improvement in Chinese ED patients after administration of two doses of Stendra 100 mg & 200 mg. Such proven clinical effectiveness may strengthen Strenda's (Avanafil) position in the market. However, lack of awareness about erectile dysfunction, shame about treatment, false-positive beliefs, social stigma pertaining to the disease, and lack of discretion may restrain the market growth. As per the survey conducted by the European Association of Urology (EAU), only 18% of the Spanish population heard about ED treatment, whereas 68.0% of the population believes the treatment benefits.

Erectile Dysfunction Drugs Market Report Highlights:

  • By product, the viagra segment held the largest market share in 2022 due to the worldwide availability of Viagra and increased awareness about the product among ED patients
  • North America dominated the erectile dysfunction drugs market and accounted for a revenue share of 51.3% in 2022, due to the high burden of disease, strong healthcare infrastructure, and rapid approval of new products for treatment in the region.
  • Asia Pacific is expected to advance at the fastest CAGR of 10.2% during the forecast period. The growth of the region is attributable to the entry of new products into the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Erectile Dysfunction Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Erectile Dysfunction Drugs Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Erectile Dysfunction Drugs Market: Product Estimates & Trend Analysis

  • 4.1. Erectile Dysfunction Drugs Market: Key Takeaways
  • 4.2. Erectile Dysfunction Drugs Market: Product Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Viagra
    • 4.3.1. Viagra market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Cialis
    • 4.4.1. Cialis market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Zydena
    • 4.5.1. Zydena market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Levitra
    • 4.6.1. Levitra market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Stendra
    • 4.7.1. Stendra market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Erectile Dysfunction Drugs Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Outlook
  • 5.2. Erectile Dysfunction Drugs Market by Region: Key Takeaways
  • 5.3. North America
    • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.3. France
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.6. Sweden
      • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.7. Norway
      • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.8. Denmark
      • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.2. China
      • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.3. India
      • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.5. Thailand
      • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.6. South Korea
      • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.2. Mexico
      • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7. MEA
    • 5.7.1. Saudi Arabia
      • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.2. South Africa
      • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Market Participant Categorization
    • 6.2.1. Pfizer, Inc.
      • 6.2.1.1. Company overview
      • 6.2.1.2. Financial performance
      • 6.2.1.3. Product benchmarking
      • 6.2.1.4. Strategic initiatives
    • 6.2.2. Eli Lilly and Company
      • 6.2.2.1. Company overview
      • 6.2.2.2. Financial performance
      • 6.2.2.3. Product benchmarking
      • 6.2.2.4. Strategic initiatives
    • 6.2.3. Teva Pharmaceutical Industries Ltd.
      • 6.2.3.1. Company overview
      • 6.2.3.2. Financial performance
      • 6.2.3.3. Product benchmarking
      • 6.2.3.4. Strategic initiatives
    • 6.2.4. Sanofi
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. Sun Pharmaceutical Industries Ltd.
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. Bayer AG
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. Petros Pharmaceuticals, Inc.
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives
    • 6.2.8. VIVUS, Inc.
      • 6.2.8.1. Company overview
      • 6.2.8.2. Financial performance
      • 6.2.8.3. Product benchmarking
      • 6.2.8.4. Strategic initiatives
    • 6.2.9. Auxilium Pharmaceuticals
      • 6.2.9.1. Company overview
      • 6.2.9.2. Financial performance
      • 6.2.9.3. Product benchmarking
      • 6.2.9.4. Strategic initiatives
    • 6.2.10. Adamed
      • 6.2.10.1. Company overview
      • 6.2.10.2. Financial performance
      • 6.2.10.3. Product benchmarking
      • 6.2.10.4. Strategic initiatives
    • 6.2.11. Cipla Inc.
      • 6.2.11.1. Company overview
      • 6.2.11.2. Financial performance
      • 6.2.11.3. Product benchmarking
      • 6.2.11.4. Strategic initiatives